research · International · Manufacturer-reported phase III topline results
Remibrutinib: phase III MS results announced
Novartis · published 2026-09-01 · approved by our editors 9/7/2026
Novartis reports that remibrutinib reduced relapse rates compared with teriflunomide in two phase III studies of relapsing MS. These are initial manufacturer results, with fuller data planned for a scientific meeting. The company plans applications for MS regulatory approval.
What this means
These are sponsor-reported results. A planned application is not an MS approval, and the release does not establish comparative disability benefit for an individual patient.
Read the original
This is our short summary. The full article belongs to Novartis (manufacturer_release).
Read the original articleNovartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials